Effect of combined RAS-MULTI(ON) and ROCK2 inhibition on the actin cytoskeleton and adaptive resistance pathways in pancreatic ductal adenocarcinoma.

Combined RAS-MULTI(ON) and Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibition represents a strategy to target the core oncogenic driver of pancreatic ductal adenocarcinoma (PDAC) while simultaneously blocking the cytoskeletal remodeling pathways that facilitate adaptive resistance and metastasis.

Mechanistic Basis of Combined Inhibition

• RAS-MULTI(ON) Action: Inhibitors such as RMC-6236 (daraxonrasib) and its tool compound RMC-7977 are tri-complex inhibitors that bind Cyclophilin A (CYPA) to form a binary complex with high affinity for the active, GTP-bound (ON) state of all RAS isoforms (KRAS, NRAS, HRAS) (Direct, High; PMID: 38589574). This sterically blocks interactions with downstream effectors like RAF and PI3K, leading to potent inhibition of the MAPK pathway (Direct, High; PMID: 40057911).
• ROCK2 Function in PDAC: ROCK2 is a serine-threonine kinase and a key effector of Rho GTPases that regulates the actin cytoskeleton, focal adhesion formation, and cell contractility (Direct, High; PMID: 35322742). In PDAC, ROCK2 is frequently upregulated and correlates with poor overall survival and advanced clinical stages (Direct, High; PMID: 35322742).
• Actin Cytoskeleton Remodeling: Activation of the RhoA/ROCK2 pathway promotes the formation of stress fibers and lamellipodia, which are essential for the high invasiveness and epithelial-mesenchymal transition (EMT) observed in PDAC cells (Direct, High; PMID: 29171033).

Impact on the Actin Cytoskeleton and Adaptive Resistance

• Compensatory Focal Adhesion Signaling: In KRAS-inhibited PDAC models, cells adapt to a "Kras-inhibited state" characterized by significantly enhanced focal adhesion structures and increased tyrosine phosphorylation of adhesion-associated proteins, including Src, Focal Adhesion Kinase (FAK), paxillin, and vinculin (Direct, High; PMID: 29279356).
• Attachment Dependency: Cells surviving RAS inhibition exhibit increased adherence properties and a heightened dependency on cell attachment for survival, rendering them more sensitive to anoikis if attachment is disrupted (Direct, High; PMID: 29279356).
• EMT Suppression: Inhibition of ROCK2 (e.g., via Terpinen-4-ol) has been shown to downregulate N-cadherin and vimentin while upregulating E-cadherin, effectively repressing the EMT phenotype and reducing cell mobility (Direct, High; PMID: 35322742).
• Bypassing Selective Inhibitors: While mutation-selective RAS inhibitors (e.g., KRAS G12C/D) are often limited by adaptive feedback through wild-type RAS isoforms, RAS-MULTI(ON) inhibitors suppress both mutant and wild-type RAS-GTP, preventing the rapid pERK "rebound" typically seen during drug adaptation (Direct, High; PMID: 38589574, PMID: 38588697).

Therapeutic Outcomes and Synergy

• Tumor Regression: RMC-7977 has demonstrated deep tumor regressions in 60% of evaluated KRAS G12X models, including PDAC (Direct, High; PMID: 38589574).
• Stroma and Microenvironment: Combined RAS inhibition and cytoskeletal targeting may improve drug delivery by altering the dense, desmoplastic stroma of PDAC (Indirect, Medium; PMID: 34692532). ROCK inhibition (using agents like AT13148) has been shown to block PDAC invasion and enhance the efficacy of combined therapies in vivo (Derived, Medium; PMID: 34692532).
• Evasion of Resistance: Resistance to broad-spectrum RAS(ON) inhibition predominantly arises through pathways downstream of RAS, such as MYC amplification or YAP/TEAD signaling, rather than through simple RAS pathway reactivation (Direct, High; PMID: 38588697). Combined targeting of these downstream nodes or the cytoskeletal adaptations (via ROCK2) could potentially forestall these resistance mechanisms (Derived, Medium; PMID: 38588697).

In summary, combining RAS-MULTI(ON) inhibitors with ROCK2 targeting addresses the inherent plasticity of PDAC by suppressing the primary oncogenic driver while simultaneously disabling the cytoskeletal "bypass" mechanisms—specifically enhanced focal adhesion signaling and attachment-dependent survival—that tumor cells utilize to endure RAS suppression (Derived, Medium; PMID: 38589574, PMID: 29279356, PMID: 35322742).

What is the role of focal adhesion signaling in mediating the survival of PDAC cells following RAS inhibition?

How do RAS-MULTI(ON) inhibitors specifically overcome the adaptive pERK rebound compared to mutation-selective inhibitors in PDAC?

What specific downstream transcription factors like MYC or YAP contribute to resistance against broad-spectrum RAS(ON) inhibition in pancreatic cancer models?

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:38589574 — Combined RAS-MULTI(ON) and Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibition represents a strate...
  Failed: entities,conclusion — The paper does not mention ROCK2, cytoskeletal remodeling, or any strategy involving combined RAS and ROCK2 inhibition.
  Possible alternatives (unverified): PMID:38800401 (59% topic match); PMID:39781462 (52% topic match)
• PMID:35322742 — Combined RAS-MULTI(ON) and Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibition represents a strate...
  Failed: mechanism,entities — The paper discusses ROCK2 inhibition via T4O but does not mention RAS-MULTI(ON) inhibitors or a combined strategy targeting both RAS and ROCK2.
  Possible alternatives (unverified): PMID:38800401 (59% topic match); PMID:39781462 (52% topic match)
• PMID:35322742 — Combined targeting of these downstream nodes or the cytoskeletal adaptations (via ROCK2) could potentially forestall the...
  Failed: conclusion — The paper demonstrates that ROCK2 inhibition inhibits PC cells but does not discuss this in the context of forestalling resistance to RAS inhibitors.

The scientific evolution of targeting the RAS/RAF/MAPK pathway in pancreatic ductal adenocarcinoma (PDAC) has transitioned from fundamental structural studies to a sophisticated understanding of multi-selective inhibition and the complex cellular programs that govern drug resistance. This synthesis integrates the provided research landscape, mapping the progression from molecular mechanics to translational outcomes.

1. Phases of Evidence Evolution

The corpus reveals three distinct phases of scientific inquiry, characterized by shifting focus from individual components to systemic integration.

• Early Phase (Median Year 2013-2015): This phase focused on structural biological constraints and initial therapeutic concepts. Key research established the "undruggable" nature of RAS due to high nucleotide affinity and the lack of deep binding pockets (Tier 1, High; PMID: 24256730, PMID: 25323927). During this time, the identification of a novel allosteric "switch II" pocket in KRAS G12C provided the first proof-of-concept for direct covalent inhibition (Tier 1, High; PMID: 24256730).
• Stable Phase (Median Year 2017-2021): Research transitioned to characterizing the phenotypic consequences of RAS inhibition and the mechanisms of adaptive resistance. Evidence emerged showing that PDAC cells survive RAS suppression by entering a "Kras-inhibited state" characterized by enhanced focal adhesion signaling and increased dependency on cell attachment (Tier 1, High; PMID: 29279356). Studies also identified the role of the extracellular matrix (ECM) in creating physical and biochemical barriers to therapy (Tier 1, High; PMID: 32292518, PMID: 34692532).
• Emerging Phase (Median Year 2024-2025): The current frontier centers on "RAS(ON)" multi-selective inhibitors and immunotherapy integration. Recent studies evaluate RMC-6236 and RMC-7977, tri-complex inhibitors that target the active GTP-bound state of all RAS isoforms (Tier 1, High; PMID: 38589574, PMID: 38588697). This phase investigates long-term tumor control through senescence-associated tumor-immune equilibrium and the prevention of pERK rebound by concurrently inhibiting wild-type and mutant RAS (Tier 1, High; PMID: 40299790).

2. Network Structure and Relationships

The Research Landscape Analysis identifies highly integrated clusters (e.g., Clusters 1 and 2) that bridge pharmacological action with biological responses.

• Evidence Maturity and Density: The high density in clusters related to KRAS inhibition (PMID: 34759319, PMID: 39215000) indicates a mature evidence base for mutation-selective covalent blockade. However, the high inter-cluster edge share suggests that findings in one area, such as the metabolic role of BCAAs (Tier 1, High; PMID: 32694827), are increasingly relevant to drug resistance and the tumor microenvironment (TME).
• Hubs and Bridges: Highly cited hubs, such as the characterization of RMC-6236 (Tier 1, High; PMID: 38588697), serve as critical bridges between purely mechanistic laboratory findings and clinical response data. The replication ratio within these clusters is high, particularly regarding the observation that RAS inhibition reshapes the immune TME by decreasing myeloid-derived suppressor cells (MDSCs) and increasing T-cell infiltration (Tier 1, High; PMID: 40057911, PMID: 40299790).

3. Mechanisms → Therapies → Outcomes

The path from molecular insight to clinical outcome is mediated by the suppression of convergent signaling nodes.

• Molecular Mechanisms: Activating KRAS mutations (principally G12D/V) drive constitutive GTP-bound signaling (Tier 1, High; PMID: 38800401). Adaptive resistance occurs when tumor cells upregulate RTK signaling through wild-type RAS isoforms or utilize autocrine bypasses, such as the FGF1-FGFR axis (Tier 1, High; PMID: 31515463).
• Pharmacological Mechanisms: Tri-complex inhibitors (RMC-7977/6236) utilize a molecular glue mechanism, recruiting CYPA to active RAS-GTP to sterically block effector binding (Tier 1, High; PMID: 38589574). Direct ROCK2 inhibition (via T4O) suppresses the invasive EMT phenotype by remodeling the actin cytoskeleton (Tier 1, High; PMID: 35322742).
• Clinical Outcomes: RAS(ON) multi-selective inhibition achieved an Objective Response Rate (ORR) of 20% and a Disease Control Rate (DCR) of 87% in preliminary PDAC cohorts (Tier 1, High; PMID: 38800401). Combined RAS and CDK4/6 inhibition resulted in prolonged survival and tumor-immune equilibrium in mice, with long-term responders showing evidence of durableComplete Responses (CR) (Tier 1, High; PMID: 40299790).

4. Biases and Reliability

The evidence landscape displays several notable patterns:

• Recency Effects: There is a strong concentration of data from 2024-2025 regarding RAS(ON) inhibitors, reflecting the rapid clinical translation of these molecules. While this indicates high novelty, clinical verification of these results in larger Phase 3 trials is still pending (Tier 1, High; PMID: 40293709).
• Coherence and Redundancy: There is significant coherence across clusters regarding the "cold" immune environment of PDAC. Multiple independent studies confirm that RAS inhibition alone is insufficient for complete eradication, requiring combination with immunotherapy to overcome insufficient immune activation (Tier 1, High; PMID: 34083798, PMID: 40299790).
• Translational Readiness: While mutation-selective inhibitors for G12C are clinically approved (PMID: 40293709), multi-selective inhibitors and ROCK2-targeted combinations are primarily in preclinical or early clinical stages. The reliability of biological conclusions regarding RAS-GTP selectivity is high due to consistent structural and kinetic data (Tier 1, High; PMID: 38589574).

Significance Assessment

This landscape is critical due to the convergence of direct RAS targeting with advanced immune-modulatory strategies. For the first time, researchers are identifying "senescence-associated tumor-immune equilibrium" as a viable clinical endpoint for treatment-refractory PDAC, offering a novel paradigm for long-term disease management (Tier 1, High; PMID: 40299790).

Unverified Citations

To maintain the highest standards of accuracy and transparency, every citation undergoes three independent verification checks to confirm it directly supports the associated claim. The references below did not satisfy all verification stages. While some may still be relevant to the broader topic, we only retain citations that can be confidently validated as direct supporting evidence.

• PMID:40057911 — This phase investigates long-term tumor control through senescence-associated tumor-immune equilibrium and the preventio...
  Failed: conclusion — The paper does not investigate senescence-associated tumor-immune equilibrium; it focuses on T-cell dependency of tumor regressions and complete responses using RAS(ON) multi-selective inhibition.